Tumour Markers in Prostatic Cancer: Prostatic Acid Phosphatase (PAP), Prostatic Specific Antigen (PSA) and Lipid Associated Sialic Acid (LASA)

1994 ◽  
Vol 61 (4) ◽  
pp. 277-280
Author(s):  
B. Garibaldi ◽  
N. Rizzello ◽  
S. Rocca Rossetti ◽  
M. Tasso ◽  
A. Tizzani ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Sialic Acid ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Cellular Membrane ◽  
Tumour Marker ◽  
Tumour Markers ◽  
Clinical Value ◽  
Tumour Extension

Among tumour markers in clinical practice, interest has been aroused by the products of the cellular membrane, such as LASA (Lipid Associated Sialic Acid). The aim of our work was to assess the clinical value of LASA in patients affected by prostatic cancer at different stages and grades, and to compare the usefulness of LASA as a tumour marker over Prostate Acid Phosphatase (PAP) and Prostate Specific Antigen (PSA), which are well known markers of tumour extension in prostatic cancer. In this study we perfomed serum dosage of LASA, PAP and PSA in fifty-five patients with prostatic adenocarcinoma, 10 cases of stage A1/A2, 13 B1/B2, 6 C1/C2 and 26 D1/D2. This study shows that LASA may complement diagnostic and prognostic values of other existing tumour markers for prostate cancer.

Clinical Usefulness of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Patients with Prostatic Cancer

Tumor Biology ◽  
1990 ◽  
Vol 11 (6) ◽  
pp. 289-294 ◽  
Author(s):  
X. Filella ◽  
R. Molina ◽  
J. Jo ◽  
B. Umbert ◽  
J.L. Bedini ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Clinical Usefulness

Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.

1986 ◽  
Vol 32 (11) ◽  
pp. 2040-2043 ◽  
Author(s):  
J K Siddall ◽  
S D Shetty ◽  
E H Cooper
Keyword(s):  
Acid Phosphatase ◽  
Disease Progression ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Carcinoma Of The Prostate ◽  
Normal Limits ◽  
Bony Metastases

Abstract We have compared the concentrations in serum of gamma-seminoprotein (gamma-SM) and prostate specific antigen (PSA), two antigens of prostatic origin that are synthesized independently of prostatic acid phosphatase (PAP, EC 3.1.3.2), to assess their potential in monitoring prostatic cancer. At presentation, 27/30 (90%) patients with metastases had a PSA concentration greater than 10 ng/mL, and 29/30 (97%) a gamma-SM concentration greater than 10 ng/mL; 21/61 (34%) with disease but without metastases had an abnormal content of PSA, and 23/61 (38%) an abnormal gamma-SM. Concentrations of PSA and gamma-SM were significantly correlated (r = 0.68, p less than 0.001). In 20 patients without metastases followed longitudinally, the median concentrations of gamma-SM, PSA, and PAP in the 13 patients who developed bony metastases or showed signs of local spreading of the tumor were 58 ng/mL, 34 ng/mL, and 2.1 U/L, respectively. The corresponding median values in the seven patients who remained clinically stable were 2.5 and 3.9 ng/mL, and 2.3 U/L. We conclude that either PSA or gamma-SM can warn of disease progression when PAP activities are still within normal limits.

Diagnostic Value of Prostatic Acid Phosphatase (Pap) and Prostate-Specific Antigen (Psa) in Patients with Prostatic Cancer

1992 ◽  
Vol 59 (1) ◽  
pp. 101-103
Author(s):  
T. Zambolin ◽  
L. Tralce ◽  
A. Cozzoli ◽  
E. Frego ◽  
C. Simeone ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Diagnostic Value ◽  
High Risk Population ◽  
Specific Substrate ◽  
Clinical Value ◽  
Receiver Operating Characteristic Curves ◽  
Clinical Accuracy

Prostatic acid phosphatase (PAP) and specific prostatic antigen (PSA) in the serum of patients with prostatic carcinoma were determined and their clinical value compared. 128 patients were examined, 60 (46.9%) of whom had prostatic carcinoma (4 in stage T2, 27 in T3 and 29 in T4) and 68 with benign prostatic pathology. ROC (receiver operating characteristic) curves were plotted from resulting data and the underlying areas calculated to evaluate the clinical accuracy of the two markers. The area for PSA (0.90 +/-0.03) was significantly greater than that for PAP (0.71 +/-0.05), showing that PSA was better at detecting patients with or without prostatic carcinoma. Maximum clinical accuracy was 0.883 obtained with discriminating values of 0.8 U/L for PAP and 10 ug/L for PSA, confirming the superiority of PSA. However, PAP determination using thymolphthalein monophosphate as the specific substrate for the prostatic isoenzyme, showed greater clinical specificity (98.5%) so that association of the two markers made it possible to eliminate false positive results. In conclusion, results suggest the possibility of using PSA for diagnosing prostatic carcinoma in a selected high risk population. However, the simplicity of the method used for determining PAP and the greater clinical specificity of PAP and PSA combined, suggest determining both parameters for diagnostic purposes.

Sign in / Sign up

Export Citation Format

Share Document